A phase II study assessed the effectiveness of combination immunotherapy with anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) (ipilimumab) and anti-PD-1 (nivolumab) in patients with rare cancers, including advanced NETs, showing an ORR of 43%. Here, CTLA4 is linked to cancer.